In a 38-year-old male presenting with abdominal distension, enlarged portal veins, night sweats, no abdominal pain, and elevated C-reactive protein, what is the appropriate diagnostic work‑up and initial management?

Immediate Diagnostic Work-Up and Management

This 38-year-old male with enlarged portal veins, abdominal bloating, night sweats, and elevated CRP requires urgent imaging with Doppler ultrasound followed by CT with contrast to diagnose portal vein thrombosis or non-cirrhotic portal hypertension, with immediate investigation for underlying myeloproliferative neoplasm given the constellation of symptoms.

Clinical Reasoning

The combination of enlarged portal veins, systemic symptoms (night sweats), elevated inflammatory markers (CRP), and young age in the absence of pain strongly suggests non-cirrhotic portal hypertension, most likely from either:

• Portal vein thrombosis (PVT) - particularly concerning given the acute presentation
• Myeloproliferative neoplasm (MPN) - the most common cause of splanchnic thrombosis in non-cirrhotic patients 1

The night sweats and elevated CRP are particularly concerning for an underlying MPN, which can present with extensive splanchnic vein thrombosis even in early stages 2. Abdominal pain with elevated CRP is a hallmark of acute PVT 3.

Immediate Diagnostic Algorithm

Step 1: Urgent Imaging (Within 24 Hours)

• Doppler ultrasound as first-line investigation 1

  • Look for: portal vein patency, flow direction, collateral vessels, splenomegaly
  • Presence of portosystemic collaterals or reversed portal flow = 100% specific for clinically significant portal hypertension 4

• CT abdomen with IV contrast (arterial, portal, and delayed phases) for diagnostic confirmation 1, 3

  • Assess extent of thrombosis (portal, splenic, superior mesenteric veins)
  • Critical: Rule out mesenteric ischemia - look for bowel wall thickening, pneumatosis, ascites
  • Evaluate liver morphology for cirrhosis

Step 2: Laboratory Work-Up (Stat)

Prothrombotic screening (mandatory in non-cirrhotic PVT):

• JAK2 V617F mutation - present in 95% of polycythemia vera, 50-60% of essential thrombocythemia and primary myelofibrosis 2
• Complete blood count with differential (look for thrombocytosis, leukocytosis)
• Peripheral blood smear
• Antiphospholipid antibodies
• Protein C, Protein S, Antithrombin III
• Factor V Leiden, Prothrombin G20210A mutation
• Homocysteine level 5

Liver function assessment:

• Comprehensive metabolic panel, liver enzymes
• Albumin, INR, bilirubin
• Hepatitis B and C serology
• Liver stiffness measurement (FibroScan) if available - >20-25 kPa suggests cirrhosis 4

Inflammatory markers:

• Lactate dehydrogenase (elevated in MPNs)
• Lactate level (if mesenteric ischemia suspected)

Step 3: Risk Stratification for Mesenteric Ischemia

Immediate surgical consultation if ANY of the following:

• Peritoneal signs on exam (despite current absence of guarding, reassess frequently)
• Hyperlactatemia
• Organ failure
• CT evidence of bowel ischemia 3

This is a medical and surgical emergency with high mortality if missed.

Initial Management

Anticoagulation Decision

Start anticoagulation immediately if imaging confirms acute PVT and no contraindications exist 1, 6, 3:

Indications favoring anticoagulation (this patient likely meets criteria):

• Acute thrombus
• Absence of cavernous transformation
• Extension into mesenteric veins
• Young age without cirrhosis

Contraindications to assess:

• Active bleeding
• Large esophageal varices (requires endoscopy)
• Severe thrombocytopenia (<50,000)

Anticoagulation regimen:

• Low-molecular-weight heparin initially (safer in potential liver disease) 7, 6
• Transition to direct oral anticoagulant (DOAC) once stable - superior to warfarin for PVT with better recanalization rates and similar bleeding risk 7
• Duration: Long-term anticoagulation indicated if MPN confirmed 1

If Myeloproliferative Neoplasm Confirmed

• Permanent anticoagulation mandatory 1
• Hematology referral for cytoreductive therapy
• The JAK2 mutation itself is a prothrombotic risk factor requiring indefinite anticoagulation 2

Common Pitfalls to Avoid

1. Assuming cirrhosis without proof: In Western countries, cirrhosis is the most common cause of portal hypertension 8, but this young patient with night sweats and no stigmata of chronic liver disease likely has a different etiology

2. Missing mesenteric ischemia: Abdominal pain with elevated CRP in PVT mandates aggressive imaging to exclude bowel ischemia 3. The absence of guarding does NOT exclude early ischemia

3. Delaying MPN work-up: MPNs are the most common cause of non-cirrhotic splanchnic thrombosis 1. JAK2 testing should be sent immediately, not after other causes are excluded

4. Underestimating recanalization potential: Early anticoagulation (within 2 weeks) offers the best chance of portal vein recanalization 7. Delay worsens outcomes

5. Forgetting endoscopy: Once acute management is complete, upper endoscopy is needed to screen for varices before long-term anticoagulation 1

Prognosis Considerations

The presence of portal hypertension significantly impacts mortality. If this represents decompensated cirrhosis with ascites, 5-year survival drops from 80% to 50% 8. However, if this is non-cirrhotic portal hypertension from PVT, prognosis is substantially better with appropriate anticoagulation and treatment of underlying MPN 6.

The key determinant of outcome is rapid diagnosis and initiation of anticoagulation before irreversible complications develop 3.